Abstract
Objectives
Majoon-e-Seer Alvi Khan, a compound Unani formulation, has been indicated in disease conditions simulating dyslipidemia. The present study was done to substantiate the efficacy of Majoon-e-Seer Alvi Khan (MSAK) in dyslipidaemia on scientific parameters.
Methods
A randomized, single-blind, Standard controlled, clinical trial was carried out on 40 patients of dyslipidemia who were randomly allocated into test (n=30) and control (n=10) groups. The test drug, MSAK, and control drug, tablet Atorvastatin was given to the respective group for 60 days along with lifestyle modification.
Results
The test drug significantly alleviated the symptoms of subjective parameters (p<0.05). There was a statistically significant reduction in lipid profile of the patients in the test group (p<0.05) than control drug treatment.
Conclusions
The study evidenced that Majoon-e-Seer Alvi Khan is potentially effective and safe in the treatment of dyslipidemia. However, a multicentre study with a robust study design is required to generalize the results.
Acknowledgments
We author are highly gratefulness to the Director of National Institute of Unani Medicine (NIUM), Bengaluru, for providing appropriate facilities to carry out the research work. We also thank to the participants who are enrolled for this study and Dr. K.P Suresh, Biostatistician for statistical analysis.
-
Research funding: None declared.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: Authors state no conflict of interest.
-
Informed consent: Informed consent was obtained from all individuals included in this study.
-
Ethical approval: Institutional Ethical Committee (NIUM/IEC/ PG/IEC/2015-16/008/Moal/08) had approved the clinical trial.
References
1. Munjal, YP, Sharm, SK. API Textbook of Medicine, Two Volume Set. New Delhi: JP Medical Ltd; 2012:1235–39 pp.Search in Google Scholar
2. Alam, S, Alam, MD, Quamri, MA, Sofi, G, Khan, MQ, Ansari, S. A Randomized single blind controlled clinical trial on safety and efficacy of a Unani formulation (Itrifal-e-Sagheer) in dyslipidemia. Cell Med 2020;10:8–1.Search in Google Scholar
3. Fukushima, K, Harada, S, Takeuchi, A, Kurihara, A, Iida, M, Fukai, K, et al.. Association between dyslipidemia and plasma levels of branched-chain amino acids in the Japanese population without diabetes mellitus. J Clin Lipidol 2019;13:932–9. https://doi.org/10.1016/j.jacl.2019.09.002.Search in Google Scholar PubMed
4. Nag, T, Ghosh, A. Cardiovascular disease risk factors in Asian Indian population: a systematic review. J Cardiovasc Dis Res 2013;4:222–8. https://doi.org/10.1016/j.jcdr.2014.01.004.Search in Google Scholar PubMed PubMed Central
5. Enas, EA, Chacko, V, Pazhoor, SG, Chennikkara, H, Devarapalli, HP. Dyslipidemia in South Asian patients. Curr Atherosclerosis Rep 2007;9:367–74. https://doi.org/10.1007/s11883-007-0047-y.Search in Google Scholar PubMed
6. Balarajan, R. Ethnicity and variations in the nation’s health. Health Trends 1996;27:114–9.Search in Google Scholar
7. Nelson, RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care Clin Off Pract 2013;40:195–211. https://doi.org/10.1016/j.pop.2012.11.003.Search in Google Scholar PubMed PubMed Central
8. Boekholdt, SM, Arsenault, BJ, Mora, S, Pedersen, TR, LaRosa, JC, Nestel, PJ, et al.. Association of LDL cholesterol, non–HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. J Am Med Assoc 2012;307:1302–9. https://doi.org/10.1001/jama.2012.366.Search in Google Scholar PubMed
9. Biswas, P, Yunus, FM, Hossan, T, Ahmed, S. Detection of lipoprotein (a)-cholesterol expression in Bangladeshi adults with dyslipidemia. Int J Publ Health Sci 2019;8:287–93. https://doi.org/10.11591/ijphs.v8i3.20060.Search in Google Scholar
10. Noubiap, JJN, Nansseu, JRN, Bigna, JJR, Jigni, AM, Kengne, AP. Prevalence and incidence of dyslipidemia among adults in Africa: a systematic review and metaanalysis protocol. BMJ 2015;5:e007404. https://doi.org/10.1136/bmjopen-2014-007404.Search in Google Scholar PubMed PubMed Central
11. Gupta, R, Rao, RS, Misra, A, Sharma, SK. Recent trends in epidemiology of dyslipidemias in India. Indian Heart J 2017;69:382–92. https://doi.org/10.1016/j.ihj.2017.02.020.Search in Google Scholar PubMed PubMed Central
12. Kwiterovich, PO. Primary and secondary disorders of lipid metabolism in pediatrics. Pediatr Endocrinol Rev 2008;2(5 Suppl):727–38.Search in Google Scholar
13. Yang, S, Hwang, JS, Park, HK, Lee, HS, Kim, HS, Kim, EY, et al.. Serum lipid concentrations, prevalence of dyslipidemia, and percentage eligible for pharmacological treatment of Korean children and adolescents; data from the Korea National Health and Nutrition Examination Survey IV (2007-2009). PloS One 2012;7:e49253. https://doi.org/10.1371/journal.pone.0049253.Search in Google Scholar PubMed PubMed Central
14. Rader, DJ, Hoeg, JM, Brewer, HB. Quantitation of plasma apolipoproteins in the primary and secondary prevention of coronary artery disease. Ann Intern Med 1994;120:1012–25. https://doi.org/10.7326/0003-4819-120-12-199406150-00008.Search in Google Scholar PubMed
15. Defesche, JC, Gidding, SS, Harada-Shiba, M, Hegele, RA, Santos, RD, Wierzbicki, AS. Familial hypercholesterolaemia. Nat Rev Dis Primers 2017;3:17093. https://doi.org/10.1038/nrdp.2017.93.Search in Google Scholar PubMed
16. Centers for Disease Control and Prevention (CDC). Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol--United States, 1999-2002 and 2005-200. MMWR Morb Mortal Wkly Rep 2011;60:109–14.Search in Google Scholar
17. Lugo-Somolinos, A, Sánchez, JE. Xanthomas: a marker for hyperlipidemias. Bol Asoc Med P R 2003;95:12–6.Search in Google Scholar
18. Fredrickson, DS. An international classification of hyperlipidemias and hyperlipoproteinemias. Ann Intern Med 1971;75:471–2. https://doi.org/10.7326/0003-4819-75-3-471.Search in Google Scholar PubMed
19. Jahangir, U, Khan, AA, Kapoor, P, Jalees, F, Urooj, S. Evaluation of a classical Unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: a randomized, standard controlled clinical study. J Pharm BioAllied Sci 2014;6:167–79. https://doi.org/10.4103/0975-7406.130975.Search in Google Scholar PubMed PubMed Central
20. Alam, S, Alam, A, Eqbal, K, Quamri, MA, Sofi, G. Approach of understanding dyslipidemia in Unani medicine. Pharma Innovation J 2018;7:235–7.Search in Google Scholar
21. Alam, MA, Quamri, MA, Sofi, G, Ansari, S. Update of hypothyroidism and its management in Unani medicine. J Basic Clin Physiol Pharmacol 2020;32:1–10.10.1515/jbcpp-2020-0121Search in Google Scholar PubMed
22. Alam, A, Ahmed, Z, Quamri, MA. Time tested safe and effect oriented drugs in Unani medicine for dyslipidemia-A review. J Homeopathy Ayurvedic Med 2015;4:2167–1206. https://doi.org/10.4172/2167-1206.1000176.Search in Google Scholar
23. Al-Amin, ZM, Thomson, M, Al-Qattan, KK, Peltonen-Shalaby, R, Ali, M. Anti-diabetic and hypolipidaemic properties of ginger (Zingiberofficinale) in streptozotocin-induced diabetic rats. Br J Nutr 2006;96:660–6. https://doi.org/10.1079/bjn20061849.Search in Google Scholar PubMed
24. Karimi, I, Hayatgheybi, H, Razmjo, M, Yousefi, M, Dadyan, A, Hadipour, M. Anti-hyperlipidaemic effects of an essential oil of Melissa officinalis. L in cholesterol-fed rabbits. J Appl Biol Sci 2010;4:17–22.Search in Google Scholar
25. Maruthappan, V, Shree, KS. Hypolipidemic activity of haritaki (terminaliachebula) in atherogenic diet induced hyperlipidemicrats. J Adv Pharm Technol Res 2010;1:229–35.Search in Google Scholar
26. Ahir, KB, Patel, BG, Patel, SB, Mehta, FA, Jani, DK, Shah, JG. Effects of solanum nigrum fruits on lipid levels and antioxidant defenses in rats with fructose induced hyperlipidemia and hyperinsulinaemia. Pharmacologyonline 2008;3:797–807.Search in Google Scholar
27. Bhandari, U, Kanojia, R, Pillai, KK. Effect of ethanolic extract of Zingiber officinale on dyslipidemia in diabetic rats. J Ethnopharmacol 2005;97:227–30. https://doi.org/10.1016/j.jep.2004.11.011.Search in Google Scholar PubMed
28. Al-Noori, AS, Amreen, AN, Hymoor, S. Antihyperlipidemic effects of ginger extracts in alloxan-induced diabetes and propylthiouracil-induced hypothyroidism in (rats). Pharmacogn Res 2013;5:157–61.10.4103/0974-8490.112419Search in Google Scholar PubMed PubMed Central
29. Shah, SS, Shah, GB, Sing, SD, Gohil, PV, Chauhan, K, Shah, KA, et al.. Effect of piperine in the regulation of obesity-induced dyslipidemia in high-fat diet rats. Indian J Pharmacol 2011;43:296–9. https://doi.org/10.4103/0253-7613.81516.Search in Google Scholar PubMed PubMed Central
30. Varsha, D, Shubhangi, S, Mangesh, P, Naikwade, NS. Antihyperlipidemic activity of Cinnamomum tamala Nees. on high cholesterol diet induced hyperlipidemia. Int J PharmTech Res 2010;2:2517–21.Search in Google Scholar
31. Achuthan, CR, Padikala, J. Hypolipidemic effect of Alpiniagalanga (rasna) and kaempferiagalanga(kachoori). Indian J Clin Biochem 1997;12:55–8. https://doi.org/10.1007/bf02867956.Search in Google Scholar PubMed PubMed Central
32. Ashraf, R, Aamir, K, Shaikh, AR, Ahmed, T. Effects of garlic on dyslipidemia in patients with type 2 diabetes mellitus. J Ayub Med Coll Abbottabad 2005;17:60–4.Search in Google Scholar
33. Asdaq, SM, Inamdar MN. Potential of Crocus sativus (saffron) and its constituent, crocin, as hypolipidemic and antioxidant in rats. ApplBiochemBiotechnol 2010;162:358–72. https://doi.org/10.1007/s12010-009-8740-7.Search in Google Scholar PubMed
34. Singh, RB, Niaz, MA, Rastogi, V, Singh, N, Postiglione, A, Rastogi, SS. Hypolipidemic and antioxidant effects of fenugreek seeds and triphala as adjuncts to dietary therapy in patients with mild to moderate hypercholesterolemia. Perfusion 1998;11:124.Search in Google Scholar
35. Kabeeruddin, HM. Bayaz-e-Kabeer. Hyderabad Dakan: Hikmat Book Depo 1935;136. 21, 43, 129. https://doi.org/10.1038/136321b0.Search in Google Scholar
36. Kabeeruddin, H. Bayaz-e-Khas; Aejaz Publication Hose. 2006. 118–9.Search in Google Scholar
37. World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. J Am Med Assoc 2013;310:2191–4. https://doi.org/10.1001/jama.2013.281053.Search in Google Scholar PubMed
38. Tariq, M, Hussain, SJ, Asif, M, Jahan, M. Protective effect of fruit extracts of Emblicaofficinalis (Gaertn.) and Terminalia bellerica (Roxb.) in experimental myocardial necrosis in rats. Indian J Exp Biol 1977;15:485–6.Search in Google Scholar
39. Suchalatha, S, Shyamala Devi, CS. Protective effect of Terminalia chebula against experimental myocardial injury induced by isoproterenol. Indian J Exp Biol 2004;42:174–8.Search in Google Scholar
40. Ibn, S. Al- Qanoon Fil Tibb (Urdu Translation by Kantori, GH).Vol.1 New Delhi: IdaraKitabusShifa; YNM:33-4.Search in Google Scholar
41. Baitar, IA. Jamiul Mufradatul Adviawal Aghzia. New Delhi: Ministry of Health and Family Welfare, Govt. of India; 1999. p. 177–78.Search in Google Scholar
42. Ghani, N. Khazainul Advia, 2nd ed., 187–189. New Delhi: Idara KitabusShifa; 2008. p. 1352–4. 421–2.Search in Google Scholar
43. Adil, W. “Efficacy of Majoon-e-Seer Alvi Khan in Dyslipidemia” was conducted at NIUM, Hospital, Doctoral dissertation). Karnataka: Bengaluru; 2018.Search in Google Scholar
44. Danwilai, K, Konmun, J, Sripanidkulchai, B, Subongkot, S. Antioxidant activity of ginger extract as a daily supplement in cancer patients receiving adjuvant chemotherapy: a pilot study. Cancer Manag Res 2017;319:11–8. https://doi.org/10.2147/CMAR.S124016.10.2147/CMAR.S124016Search in Google Scholar PubMed PubMed Central
45. Samarghandian, S, Azimi-Nezhad, M, Farkhondeh, T. Immunomodulatory and antioxidant effects of saffron aqueous extract (Crocus sativus L.) on streptozotocininduced diabetes in rats. Indian Heart J 2017;69:151–9. https://doi.org/10.1016/j.ihj.2016.09.008.Search in Google Scholar PubMed PubMed Central
46. Chang, CL, Lin, CS. Development of antioxidant activity and pattern recognition of TerminaliachebulaRetzius extracts and its fermented products. HungKuang J 2010;61:115–29.Search in Google Scholar
© 2021 Walter de Gruyter GmbH, Berlin/Boston
